Hospital
Webster Health Services, INC.
Webster Health Services, INC. was paid $6.05M by Medicaid between Jan 2018 and Dec 2024, across 107 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoWEBSTER HEALTH SERVICES, INC.
EUPORA, MS 39744
EUPORA, MS 39744
33aNPI1982719621assigned 08/21/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.05M
24GClaims182,176
24DCodes billed107
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#42 of 77
Median peer was paid$8.23M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TOPPIN, BRUCE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32,468 | $976K | |
| 2019 | 28,311 | $907K | |
| 2020 | 20,941 | $657K | |
| 2021 | 20,650 | $763K | |
| 2022 | 24,312 | $822K | |
| 2023 | 29,324 | $1.06M | |
| 2024incomplete | 26,170 | $866K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 13,474 | 11,007 | $1.50M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 5,533 | 4,756 | $1.04M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.9% | 1,702 | 1,476 | $356K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.5% | 5,646 | 4,901 | $333K |
| 87428 | 4.3% | 4,599 | 4,121 | $263K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4.2% | 6,446 | 5,323 | $255K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.7% | 9,886 | 1,391 | $223K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.5% | 2,148 | 1,859 | $214K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.0% | 13,284 | 11,419 | $181K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.9% | 9,872 | 5,546 | $173K |
| G0378 | Hospital observation service, per hour | 2.2% | 409 | 370 | $132K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 1,283 | 1,141 | $124K |
95 more codes
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.0% | 3,735 | $123K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 1,598 | $106K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 1,918 | $94K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 2,604 | $83K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 2,216 | $80K |
| 80053 | Comprehensive metabolic panel | 1.2% | 10,024 | $71K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 13,611 | $70K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.0% | 3,134 | $61K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,065 | $57K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 439 | $42K |
| 80061 | Lipid panel | <1% | 4,033 | $41K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,445 | $36K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,796 | $35K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,220 | $26K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,318 | $24K |
| 83880 | <1% | 1,370 | $22K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 274 | $21K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 558 | $21K |
| 87420 | <1% | 1,512 | $19K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 254 | $18K |
| 80305 | <1% | 1,697 | $17K | |
| 81001 | <1% | 5,682 | $12K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,597 | $12K |
| 74018 | <1% | 256 | $11K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,942 | $11K |
| 87400 | <1% | 486 | $10K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 128 | $9K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 65 | $9K |
| 84484 | <1% | 1,629 | $9K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 38 | $9K |
| 81025 | <1% | 878 | $6K | |
| 81003 | <1% | 2,690 | $6K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 89 | $6K |
| Q3014 | Telehealth originating site facility fee | <1% | 281 | $6K |
| 83874 | <1% | 712 | $5K | |
| 82553 | <1% | 727 | $5K | |
| 87077 | <1% | 754 | $4K | |
| 83735 | <1% | 1,148 | $4K | |
| 87186 | <1% | 728 | $4K | |
| 73030 | <1% | 108 | $3K | |
| 80076 | <1% | 474 | $3K | |
| 86803 | <1% | 282 | $3K | |
| 87040 | <1% | 511 | $3K | |
| 73630 | <1% | 112 | $3K | |
| 83690 | <1% | 696 | $3K | |
| 82044 | <1% | 656 | $3K | |
| 82550 | <1% | 594 | $3K | |
| 82150 | <1% | 554 | $3K | |
| 87807 | <1% | 231 | $3K | |
| 82570 | <1% | 895 | $3K | |
| 73562 | <1% | 85 | $2K | |
| 97162 | <1% | 45 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 23 | $2K |
| 74019 | <1% | 16 | $1K | |
| 80050 | General health panel | <1% | 319 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,158 | $980.74 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 13 | $953.15 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 13 | $815.06 |
| 85610 | <1% | 336 | $802.56 | |
| 80306 | <1% | 58 | $755.31 | |
| 82948 | <1% | 264 | $706.34 | |
| 82962 | <1% | 549 | $673.50 | |
| 72100 | <1% | 16 | $644.98 | |
| 84439 | <1% | 87 | $618.98 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 24 | $551.03 |
| 72131 | <1% | 13 | $505.93 | |
| 82043 | <1% | 137 | $500.38 | |
| 85651 | <1% | 93 | $276.44 | |
| 86677 | <1% | 27 | $249.38 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,820 | $238.22 |
| 83655 | <1% | 14 | $162.20 | |
| 84703 | <1% | 25 | $160.39 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,813 | $113.58 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,459 | $64.75 |
| A9270 | Non-covered item or service | <1% | 1,584 | $63.44 |
| 83605 | <1% | 19 | $41.64 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 121 | $32.63 |
| 97166 | <1% | 13 | $32.38 | |
| 84145 | <1% | 189 | $30.40 | |
| 85652 | <1% | 14 | $27.04 | |
| 85018 | <1% | 12 | $25.62 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 88 | $19.60 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 93 | $3.35 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 578 | $2.11 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 14 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 224 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 30 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 124 | $0.00 |
| 96376 | 0% | 54 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 448 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 903 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 116 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 42 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 29 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTOPPIN, BRUCE (CORPORATE SECRETARY)
Parent organizationWEBSTER HEALTH SERVICES, INC.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.